A Pilot Bioequivalence Study Between Amphotericin B Liposome for Injection and AmBisome® in Healthy Subjects

NCT04993222 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Bioequivalence

Interventions

DRUG: Amphotericin B liposome for injection
DRUG: AmBisome®

Sponsor

CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.